The SUM-52PE cell line was the second cell line developed in the Ethier lab. This specimen that yielded this cell line was a pleural effusion specimen from a patient with metastatic breast cancer. While this specimen and cell line are ER and PR negative, they nevertheless are a luminal breast cancer cell line. Interestingly, the primary tumor from this patient and a metastatic lymph node from this patient were both ER and PR positive. Thus, the progression of this cancer that resulted in a malignant pleural effusion metastasis was associated with the loss of expression or ER and PR. The main driving oncogene in this cell line is FGFR2 that is amplified, overexpressed, and expressed as multiple splice variants. FGFR2 was found to be highly essential in our shRNA screen and the cells are highly sensitive to the FGFR targeted drug PD173074.
Okay, let’s delve more deeply into the SUM-52 cell line.
- Derivation of the SUM-52PE breast cancer cell line
- Narrative summary of the SUM-52PE cell line
- The amplified oncogenes of this cell line
- The KEGG canonical pathways enriched with data from our genome-scale shRNA screen
- The functional-druggable signature for SUM-52 cells
- SUM-52 drug sensitivity from Heiser et al.
- Bibliography of published papers in which SUM-52 cells were used
- SUM-52 Blog page
Back to the SUM cell line Gateway Page
Back to SUM-line Knowledge Base Home page
